A Single-dose, Open-label, Phase I Study Comparing the Pharmacokinetics, Safety, and Pharmacodynamics of HRS-5965 in Subjects With Mild and Moderate Hepatic Impairment and Normal Hepatic Function
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs HRS-5965 (Primary)
- Indications Liver failure
- Focus Pharmacokinetics
- 11 Dec 2024 Status changed from not yet recruiting to recruiting.
- 08 Nov 2024 New trial record